Activate Now
ProHealth fibromyalgia Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Do You Have These Fibromyalgia Symptoms of Systemic Dysfunction?

Fibromyalgia – The Savella Story

Meet Devin Starlanyl: Fibromyalgia and Chronic Myofascial Pain Expert

Which Infection Causes CFS & Fibromyalgia?

The "Mind Diet" Reduces the Risk Of Alzheimer’s Dementia. Might It Also Help the Brain Fog Found Wit...

Need Help with Pain Management? There's an App for That

Simplifying Nutritional Support in CFS & Fibromyalgia

6 Reasons Why Trigger Point Injections Aren't Helping Your Fibromyalgia

How Multiple Chronic Illnesses Shaped One Woman Into a Patient Advocate

VIDEO: Fibromyalgia & Your Stress-Coping Savings Account

Print Page
Email Article

Savella Effective for Long-Term Treatment of Fibromyalgia

  [ 1 vote ]   [ Discuss This Article ] • October 7, 2013

Note: You may download the full text of this article free HERE.

Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.

By Daniel J Clauw, et al.


INTRODUCTION: Previous studies of long-term treatment response in fibromyalgia and other chronic pain states have generally been limited to approximately a year, leaving questions about the longer-term durability of response. The purpose of this study was to demonstrate continuing efficacy of milnacipran by characterizing changes in pain and other fibromyalgia symptoms after discontinuing long-term treatment. The mean length of milnacipran treatment at time of randomized withdrawal was 36.1 months from initial exposure to milnacipran (range, 17.9 to 54.4 months).

METHODS: After completing a long-term, open-label, lead-in study of milnacipran (which followed varying periods of exposure in previous studies), adult patients with fibromyalgia entered the 4-week open-label period of the current study for evaluation of ongoing treatment response. After the 4-week period to confirm new baseline status, 151 patients taking milnacipran [greater than or equal to]100 mg/day and reporting [greater than or equal to]50% improvement from pre-milnacipran exposure in visual analog scale (VAS) pain scores were classified as responders.

These responders entered the 12-week, double-blind, withdrawal period in which they were randomized 2:1 to continue milnacipran or switch to placebo. The prespecified primary parameter was loss of therapeutic response (LTR), defined as increase in VAS pain score to <30% reduction from pre-milnacipran exposure, or worsening of fibromyalgia requiring alternative treatment. Adverse events and vital signs were also monitored.


  • Time to LTR was shorter in patients randomized to placebo than in patients continuing milnacipran (P<0.001).

  • Median time to LTR was 56 days with placebo and not calculable for milnacipran since less than half of these patients lost therapeutic response by study end.

  • Additionally, 81% of patients continuing on milnacipran maintained clinically meaningful pain response ([greater than or equal to]30% improvement from pre-milnacipran exposure), compared with 58% of patients switched to placebo (sensitivity analysis II; P<0.001).

  • Incidence of treatment-emergent adverse events was 58% and 47% for placebo and milnacipran, respectively.

  • Mean decreases in blood pressure and heart rate were found in both groups, with greater decreases for patients switched to placebo.

CONCLUSIONS: Continuing efficacy of milnacipran was demonstrated by the loss of effect following withdrawal of treatment in patients who received an average of 3 years of milnacipran treatment.

Source: Arthritis Research & Therapy, August 16, 2013. By Daniel J Clauw, Philip J Mease, Robert H Palmer, Joel M Trugman and Yong Wang.

Please Discuss This Article:   Post a Comment 

[ Be the first to comment on this article ]

Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Subscribe Now!
Receive up-to-date ME/CFS, Fibromyalgia & Lyme Disease treatment and research news
 Privacy Guaranteed  |  View Archives

Vitamins and Supplements for Fibromyalgia Support

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Guaifenesin FA™ Guaifenesin FA™
Natural Expectorant Relieves Chest Congestion
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 your brain needs for detox & sharpness
Fibro Freedom™ Fibro Freedom™
Soothes, strengthens & revitalizes
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Vitamin E: Super Antioxidant We Only Thought We Knew Vitamin E: Super Antioxidant We Only Thought We Knew
When a Negative is Positive - Goodnighties Recovery Sleepwear When a Negative is Positive - Goodnighties Recovery Sleepwear
Stop Bacteria With Nature's Antibiotics Stop Bacteria With Nature's Antibiotics
The Curcumin Revolution: 'Golden' Ticket to Better Health The Curcumin Revolution: 'Golden' Ticket to Better Health
"It's Not Easy Being Green" - But It Is Healthy

What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Causes
Fibromyalgia Treatments
Fibromyalgia Diet
Fibromyalgia Medications
M.E. & CFS
What is M.E./CFS?
M.E./CFS Diagnosis
M.E./CFS Symptoms
M.E./CFS Causes
M.E./CFS Treatments
M.E./CFS Diet
M.E./CFS Medications
What is Lyme Disease?
Lyme Disease Diagnosis
Lyme Disease Symptoms
Lyme Disease Causes
Lyme Disease Treatments
Lyme Disease Diet
Lyme Disease Medications
M.E. & CFS
Lyme Disease
General Health
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing